Compare Accenture plc (ACN) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Accenture plc vs Canopy Growth Corp — how do they compare? Accenture plc trades at $178.49 (market cap $110.24B), while Canopy Growth Corp trades at $1.02 (market cap $430.60M). The key difference: Accenture plc is far larger — about 256× Canopy Growth Corp's market cap, and Accenture plc pays a 3.62% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| ACN | CGC | |
|---|---|---|
Market Cap | $110.24B | $430.60M |
Sector | Technology | Health |
52-Week High | $288.54 | $1.92 |
52-Week Low | $124.41 | $0.86 |
Enterprise Value | $108.45B | $388.01M |
Dividend Yield | 3.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $178.49, down 0.74% on the day, with strong technical momentum showing bullish moving averages despite overbought RSI signals. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $3.80 versus $3.70, continuing a pattern of earnings outperformance. Recent strategic partnerships with TEPCO Solution Advance and AlphaSense highlight Accenture's expansion in AI-enabled business transformation services.
The investment outlook remains positive with 66% analyst buy ratings and a $189.77 consensus price target suggesting 6.3% upside potential. Key risks include competitive pressures in consulting services and potential margin compression from increased AI investments. The stock's current valuation at 14.39x P/E appears reasonable given consistent revenue growth and strong cash flow generation.
CGC trades at $1.01, up 1.0% in the last session, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 fiscal 2027 revenue growth of 13% year-over-year, beating estimates, yet continues to post net losses. Recent news highlights expansion in European medical cannabis markets and cost-cutting efforts, while analyst consensus is mixed with 33% buy ratings.
Outlook remains speculative with high execution risk; improving cash flow trends and potential U.S. rescheduling offer upside, but persistent negative margins and debt concerns weigh on equity value. Investors should weigh growth prospects against profitability challenges in the volatile cannabis sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
